Mass Treatment to Eliminate Filariasis in Papua New Guinea
Open Access
- 5 December 2002
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 347 (23), 1841-1848
- https://doi.org/10.1056/nejmoa021309
Abstract
The global initiative to eradicate bancroftian filariasis currently relies on mass treatment with four to six annual doses of antifilarial drugs. The goal is to reduce the reservoir of microfilariae in the blood to a level that is insufficient to maintain transmission by the mosquito vector.Keywords
This publication has 28 references indexed in Scilit:
- The PacELF programme: will mass drug administration be enough?Trends in Parasitology, 2002
- Ecologic and Biologic Determinants of Filarial Antigenemia in Bancroftian Filariasis in Papua New GuineaThe Journal of Infectious Diseases, 2001
- Wolbachia Bacteria of Filarial Nematodes: A Target for Control?Published by Elsevier BV ,2000
- EPIFIL: The development of an age-structured model for describing the transmission dynamics and control of lymphatic filariasisEpidemiology and Infection, 2000
- Filariose linfática: doença potencialmente eliminávelCadernos de Saude Publica, 1997
- Transmission Intensity and Its Relationship to Infection and Disease Due toWuchereria bancroftiin Papua New GuineaThe Journal of Infectious Diseases, 1997
- Past exposure and the dynamics of lymphatic filariasis infection in young childrenEpidemiology and Infection, 1996
- A Controlled Trial of Ivermectin and Diethylcarbamazine in Lymphatic FilariasisNew England Journal of Medicine, 1990
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986
- Efficacy of Diethylcarbamazine in Eradicating Infection with Lymphatic-Dwelling Filariae in HumansClinical Infectious Diseases, 1985